Gastroenterologists ‘at the forefront’ of shaping cancer care (Healio)

Upper GI cancers, including esophageal, stomach, and pancreatic cancers, remain the second leading cause of cancer-related deaths in the U.S. Gastroenterologists, with their expertise in endoscopic ultrasound (EUS), are uniquely positioned to lead the integration of emerging cancer therapies such as targeted radiotherapy. These minimally invasive, EUS-guided treatments allow for precise intratumoral delivery, especially in pancreatic cancer where surgery is often not viable. As treatment models become more collaborative and personalized, GIs are at the forefront of a care revolution—poised to drive innovation, expand access to localized therapies, and improve patient outcomes.